| Pair Name | All-trans retinoic acid, Imatinib | ||
| Phytochemical Name | All-trans retinoic acid (PubChem CID: 444795 ) | ||
| Anticancer drug Name | Imatinib (PubChem CID: 123596 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | All-trans retinoic acid, Imatinib | |||
| Disease Info | [ICD-11: 2A60.Z] | Acute myeloid leukemia | Investigative | |
| Gene Regulation | Down-regulation | Expression | ABCB1 | hsa5243 |
| Down-regulation | Expression | ABL1 | hsa25 | |
| In Vitro Model | K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 |
| Result | Combined ATRA and IM therapy was shown to be effective in decreasing BCR-ABL and ABCB1 genes, possibly through the differentiation of blast cells, demonstrating that the therapy could be potentially effective in the blast crisis of the disease and for those patients who develop resistance to available CML treatments. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model. In Vivo. 2021 Sep-Oct;35(5):2661-2667. doi: 10.21873/invivo.12549. | Click |
